Benjamin Cravatt, 31
Biotechnology
Scripps Research Institute
Chemical biologist Benjamin Cravatt is developing tools to illuminate the roles of proteins and enzymes in humans and animals. Cravatt and colleagues have synthesized dozens of fluorescent probes that chemically bind to enzymes in laboratory samples of healthy and diseased tissues, then light up when excited by a laser scanner. The technique can show which enzymes are more or less active in cancerous cells, which could herald a breakthrough for proteomics—the attempt to identify the structures and functions of human proteins. Cravatt’s protein-activity- based approach represents an advance over methods that merely infer protein function by comparing the abundance of proteins in samples. His technology also forms the basis of ActivX Biosciences in La Jolla, CA, which he cofounded in 2000 and now employs more than 40 people. Applications for the chemical probes include improving medical diagnostics, identifying new drug targets and facilitating drug tests. “Helping with the development of a single drug would be huge, ”the hyperkinetic researcher says, “but we hope to do this many times over.”
2002 TR35 Winners
Ewan Birney
Biotechnology
Stephen Boppart
Medicine
Fiona Brinkman
Biotechnology
Stephen Brossette
Medicine
Chris Burge
Biotechnology
Benjamin Cravatt
Biotechnology
Nathaniel David
Biotechnology
Jennifer Elisseeff
Medicine
Susan Hagness
Medicine
Derek Hansford
Materials
John Harrington
Medicine
Suzie Hwang Pun
Medicine
J. Joseph Kim
Medicine
Steven Laken
Medicine
Corinna E. Lathan
Medicine
Kelvin Lee
Medicine
Surya Mallapragada
Medicine
Sean J. Morrison
Medicine
Milan Mrksich
Materials
Stephen OConnor
Biotechnology
Alexander Olek
Biotechnology
Vijay Pande
Biotechnology
Stephen Quake
Materials
David Sabatini
Biotechnology
John Santini
Medicine
David Schaffer
Medicine
Kevin Shakesheff
Materials
Vivek Subramanian
Materials
Christoph Westphal
Biotechnology

